Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: Outcome assessment applying a predictive scoring system

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Damm, Robert ^a   Seidensticker, Ricarda ^a,b   Ulrich, Gerhard ^a   Breier, Leonie ^a   Steffen, Ingo G ^a   Seidensticker, Max ^a,b   Garlipp, Benjamin ^a   Mohnike, Konrad ^a,b   Pech, Maciej ^a,b   Amthauer, Holger ^a,b   Ricke, Jens ^a,b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b Deutsche Akademie für Mikrotherapie International School of Image Guided Interventions   (Germany)

Author keywords

Colorectal cancer; Liver metastases; Prognostic score; Salvage patients; Y90 radioembolization

Indexed keywords

BEVACIZUMAB; CA 19-9 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; IRINOTECAN; MICROSPHERE; MITOMYCIN; OXALIPLATIN; PANITUMUMAB; YTTRIUM 90; YTTRIUM;

ADULT; AGE; AGED; ARTICLE; ARTIFICIAL EMBOLIZATION; ASCITES; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CHOLECYSTITIS; COHORT ANALYSIS; COLORECTAL CANCER; DISEASE SEVERITY; DUODENUM ULCER; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIVER FAILURE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SELECTION; PLEURA EFFUSION; PREDICTION; PROTEIN BLOOD LEVEL; RADIATION INJURY; RADIOEMBOLIZATION; RETROSPECTIVE STUDY; SCORING SYSTEM; STOMACH ULCER; TREATMENT OUTCOME; BLOOD; COLORECTAL NEOPLASMS; DRUG RESISTANCE; KAPLAN MEIER METHOD; LIVER; LIVER NEOPLASMS; METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SECONDARY; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; YTTRIUM RADIOISOTOPES;

EID: 84978910549     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2549-x     Document Type: Article

References (19)

1. van Hazel GA, Bower G, Sharma RA, Blanshard K, Steward WP. Selective internal radiation therapy (SIRT) for liver metastases with concomitant systemic oxaliplatin, 5-fluorouracil and folinic acid: A phase I/II dose escalation study. J Clin Oncol. 2005;23:1-1087.
2. Lim L, Gibbs P, Yip D, Shapiro JD, Dowling R, Smith D, et al. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer. 2005;5:132.
3. Bester L, Meteling B, Pocock N, Saxena A, Chua TC, Morris DL. Radioembolisation with Yttrium-90 microspheres: an effective treatment modality for unresectable liver metastases. J Med Imaging Radiat Oncol. 2013;57:72-80.
4. Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer. 2010;103:324-31.
5. Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28:3687-94.
6. Seidensticker R, Denecke T, Kraus P, Seidensticker M, Mohnike K, Fahlke J, et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol. 2012;35:1066-73.
7. Van Cutsem E, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. The European Society for Medical Oncology (ESMO). Ann Oncol. 2014;25 Suppl 6:6-7.
8. Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Radioembolization for the treatment of liver tumors general principles. Am J Clin Oncol. 2012;35:91-9.
9. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13-23.
10. Seidensticker R, Seidensticker M, Damm R, Mohnike K, Schütte K, Malfertheiner P, et al. Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: sequential lobar versus whole liver approach. Cardiovasc Intervent Radiol. 2012;35:1109-18.
11. Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, et al. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol. 2011;22:265-78.
12. Gibbs P, Sharma N, Findlay M, Ricke J, Gebski V, Van Buskirk M, et al. SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2015;33: Suppl 15:3502.
13. Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, et al. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol. 2005;56:10-4.
14. Harba AJK, Kegel T, Behrens R, Grothey A, Schmoll HJ. Capecitabine/Mitomycin C as salvage therapy in oxaliplatin and CPT11 refractory advanced colorectal carcinoma. Proc Am Soc Clin Oncol. 2003;22:332.
15. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303-12.
16. Chong G, Dickson JL, Cunningham D, Norman AR, Rao S, Hill ME, et al. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer. 2005;93:510-4.
17. Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol. 2008;19:92-8.
18. Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer. 2008;112:1538-46.
19. Seidensticker M, Seidensticker R, Damm R, Mohnike K, Pech M, Sangro B, et al. Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity. PLoS One. 2014;9:112731.